Is first-line immune checkpoint inhibitors (ICI) beneficial to platinum-eligible patients (pts) with advanced urothelial carcinoma (aUC)? a meta-analysis.

被引：0
|
作者：
Cheng, Ce [1 ]
Chineke, Iloabueke Gabriel [1 ]
McBride, Ali [1 ]
Chipollini, Juan [1 ]
Gelmann, Edward Paul [1 ]
Recio-Boiles, Alejandro [1 ]
机构：
[1] Univ Arizona, Canc Ctr, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e16506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16506
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI)
    Bakaloudi, Dimitra Rafailia
    Talukder, Rafee
    Makrakis, Dimitrios
    Diamantopoulos, Leonidas Nikolaos
    Patgunarajah, Ubenthira
    Thomas, Vinay Mathew
    Jindal, Tanya
    Brown, Jason R.
    Miletic, Marija
    Johnson, Jeffrey
    Hui, Gavin
    Buznego, Lucia Alonso
    Morales-Barrera, Rafael
    Castaneda, David Humberto Marmolejo
    Nguyen, Charles B.
    Barata, Pedro C.
    Stewart, Tyler F.
    Gupta, Shilpa
    Grivas, Petros
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 654 - 654
  • [12] Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis
    Li, Haifeng
    Ni, Mengqian
    Xue, Cong
    Li, Lu
    Huang, Riqing
    Yang, Wei
    Hu, Anqi
    An, Xin
    Shi, Yanxia
    CLINICAL IMMUNOLOGY, 2022, 236
  • [13] First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
    Naito, Renato
    Izumi, Kouji
    Mizokami, Atsushi
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (03) : 986 - 990
  • [14] First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma
    Tsimafeyeu, Ilya
    Tjulandin, Sergei
    BJU INTERNATIONAL, 2019, 123 (04) : 563 - 565
  • [15] First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis
    Mori, Keiichiro
    Pradere, Benjamin
    Moschini, Marco
    Mostafaei, Hadi
    Laukhtina, Ekaterina
    Schuettfort, Victor M.
    Motlagh, Reza Sari
    Soria, Francesco
    Teoh, Jeremy Y. C.
    Egawa, Shin
    Powles, Thomas
    Shariat, Shahrokh F.
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 35 - 48
  • [16] Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis
    Yanagisawa, Takafumi
    Mori, Keiichiro
    Matsukawa, Akihiro
    Kawada, Tatsushi
    Katayama, Satoshi
    Laukhtina, Ekaterina
    Rajwa, Pawel
    Quhal, Fahad
    Pradere, Benjamin
    Fukuokaya, Wataru
    Iwatani, Kosuke
    Pichler, Renate
    Teoh, Jeremy Yuen-Chun
    Moschini, Marco
    Krajewski, Wojciech
    Miki, Jun
    Shariat, Shahrokh F.
    Kimura, Takahiro
    European Assoc Urol
    Young Acad Urologists Urothelial Carcinoma Working Grp EAU YAU
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (03)
  • [17] Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma
    Swami, Umang
    Haaland, Benjamin
    Kessel, Adam
    Nussenzveig, Roberto
    Maughan, Benjamin Louis
    Esther, John
    Sirohi, Deepika
    Pal, Sumanta K.
    Grivas, Petros
    Agarwal, Neeraj
    JOURNAL OF UROLOGY, 2021, 205 (03): : 709 - 717
  • [18] First-line treatments for cisplatin-eligible patients with metastatic urothelial carcinoma: A meta-analysis
    Mori, K.
    Pradere, B.
    Moschini, M.
    Mostafaei, H.
    Laukhtina, E.
    Schuettfort, V. M.
    Sari, Motlagh R.
    Soria, F.
    Teoh, J. Y. C.
    Quhal, F.
    Katayama, S.
    Egawa, S.
    Powles, T.
    Shariat, S. F.
    EUROPEAN UROLOGY, 2021, 79 : S1161 - S1163
  • [19] Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
    Vlachou, Evangelia
    Elias, Roy
    Hahn, Noah M.
    Mcconkey, David James
    Johnson, Burles Avner
    Hoffman-Censits, Jean H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 570 - 570
  • [20] Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma
    Talukder, Rafee
    Makrakis, Dimitrios
    Lin, Genevieve Ihsiu
    Diamantopoulos, Leonidas N.
    Dawsey, Scott
    Gupta, Shilpa
    Carril-Ajuria, Lucia
    Castellano, Daniel
    de Kouchkovsky, Ivan
    Jindal, Tanya
    Koshkin, Vadim S.
    Park, Joseph J.
    Alva, Ajjai
    Bilen, Mehmet A.
    Stewart, Tyler F.
    McKay, Rana R.
    Tripathi, Nishita
    Agarwal, Neeraj
    Vather-Wu, Naomi
    Zakharia, Yousef
    Morales-Barrera, Rafael
    Devitt, Michael E.
    Cortellini, Alessio
    Fulgenzi, Claudia Angela Maria
    Pinato, David J.
    Nelson, Ariel
    Hoimes, Christopher J.
    Gupta, Kavita
    Gartrell, Benjamin A.
    Sankin, Alex
    Tripathi, Abhishek
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Murgic, Jure
    Frobe, Ana
    Rodriguez-Vida, Alejo
    Drakaki, Alexandra
    Liu, Sandy
    Lu, Eric
    Kumar, Vivek
    Di Lorenzo, Giuseppe
    Joshi, Monika
    Isaacsson-Velho, Pedro
    Buznego, Lucia Alonso
    Duran, Ignacio
    Moses, Marcus
    Barata, Pedro
    Sonpavde, Guru
    Wright, Jonathan L.
    Yu, Evan Y.
    CLINICAL GENITOURINARY CANCER, 2022, 20 (06) : 558 - 567
12345